Cargando…

Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study

Millions of people throughout the world suffer from the acquired condition of hyperpigmentation known as melasma. Melasma is characterized by symmetrically oriented hyperpigmented macules and patches. Many treatment options are available with variable degrees of efficacy and tolerability. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Abd Elraouf, Israa Gomaa, Obaid, Zakaria Mahran, Fouda, Ibrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338558/
https://www.ncbi.nlm.nih.gov/pubmed/36856856
http://dx.doi.org/10.1007/s00403-023-02580-y
_version_ 1785071653896585216
author Abd Elraouf, Israa Gomaa
Obaid, Zakaria Mahran
Fouda, Ibrahim
author_facet Abd Elraouf, Israa Gomaa
Obaid, Zakaria Mahran
Fouda, Ibrahim
author_sort Abd Elraouf, Israa Gomaa
collection PubMed
description Millions of people throughout the world suffer from the acquired condition of hyperpigmentation known as melasma. Melasma is characterized by symmetrically oriented hyperpigmented macules and patches. Many treatment options are available with variable degrees of efficacy and tolerability. The aim of the work was to evaluate and compare the effectiveness and safety of intradermal tranexamic acid (TXA) versus intradermal platelet-rich plasma (PRP) in the treatment of various types of melasma. The current split-face prospective study included 40 cases with melasma. Tranexamic acid (TXA) was injected intradermally into the right side of the face by using a concentration of 4 mg/ml, while platelet-rich plasma (PRP) was injected intradermally into the left side. In both sides, a total of three sessions of treatment were provided, once every 4 weeks. Digital photographs were taken before each treatment session and 3 months after the last session. The modified melasma area severity index (mMASI) grading system and dermoscopy were used to assess the improvement in the condition. The disease severity and percentage of improvement were assessed by mMASI score before and after therapy across both sides of the face. along with determining the degree of satisfaction and side effects among the included cases. The mean mMASI score before therapy in the TXA side was 4.59 ± 2.87, while in the PRP side, the mean mMASI score before therapy was 4.72 ± 2.72 with no statistically significant difference between the two sides (p = 0.841). After 3 months of treatment, the mean mMASI score in the TXA-treated side was 2.49 ± 1.58 with a mean percentage of decrease of 45.67 ± 8.10%, while in the PRP side, the mean mMASI score after treatment was 2.17 ± 1.41 with a mean percentage of decrease of 53.66 ± 11.27%. There was a high statistically significant decrease in the mMASI score after treatment on both sides (p < 0.001); however, the percentage of score reduction in the PRP side compared to the TXA side was statistically higher. Intradermal injection with PRP revealed higher efficacy in the treatment of melasma as compared to TXA injection with no significant difference regarding the associated side effects.
format Online
Article
Text
id pubmed-10338558
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-103385582023-07-14 Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study Abd Elraouf, Israa Gomaa Obaid, Zakaria Mahran Fouda, Ibrahim Arch Dermatol Res Study Protocol Millions of people throughout the world suffer from the acquired condition of hyperpigmentation known as melasma. Melasma is characterized by symmetrically oriented hyperpigmented macules and patches. Many treatment options are available with variable degrees of efficacy and tolerability. The aim of the work was to evaluate and compare the effectiveness and safety of intradermal tranexamic acid (TXA) versus intradermal platelet-rich plasma (PRP) in the treatment of various types of melasma. The current split-face prospective study included 40 cases with melasma. Tranexamic acid (TXA) was injected intradermally into the right side of the face by using a concentration of 4 mg/ml, while platelet-rich plasma (PRP) was injected intradermally into the left side. In both sides, a total of three sessions of treatment were provided, once every 4 weeks. Digital photographs were taken before each treatment session and 3 months after the last session. The modified melasma area severity index (mMASI) grading system and dermoscopy were used to assess the improvement in the condition. The disease severity and percentage of improvement were assessed by mMASI score before and after therapy across both sides of the face. along with determining the degree of satisfaction and side effects among the included cases. The mean mMASI score before therapy in the TXA side was 4.59 ± 2.87, while in the PRP side, the mean mMASI score before therapy was 4.72 ± 2.72 with no statistically significant difference between the two sides (p = 0.841). After 3 months of treatment, the mean mMASI score in the TXA-treated side was 2.49 ± 1.58 with a mean percentage of decrease of 45.67 ± 8.10%, while in the PRP side, the mean mMASI score after treatment was 2.17 ± 1.41 with a mean percentage of decrease of 53.66 ± 11.27%. There was a high statistically significant decrease in the mMASI score after treatment on both sides (p < 0.001); however, the percentage of score reduction in the PRP side compared to the TXA side was statistically higher. Intradermal injection with PRP revealed higher efficacy in the treatment of melasma as compared to TXA injection with no significant difference regarding the associated side effects. Springer Berlin Heidelberg 2023-03-01 2023 /pmc/articles/PMC10338558/ /pubmed/36856856 http://dx.doi.org/10.1007/s00403-023-02580-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Study Protocol
Abd Elraouf, Israa Gomaa
Obaid, Zakaria Mahran
Fouda, Ibrahim
Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study
title Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study
title_full Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study
title_fullStr Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study
title_full_unstemmed Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study
title_short Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study
title_sort intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338558/
https://www.ncbi.nlm.nih.gov/pubmed/36856856
http://dx.doi.org/10.1007/s00403-023-02580-y
work_keys_str_mv AT abdelraoufisraagomaa intradermalinjectionoftranexamicacidversusplateletrichplasmainthetreatmentofmelasmaasplitfacecomparativestudy
AT obaidzakariamahran intradermalinjectionoftranexamicacidversusplateletrichplasmainthetreatmentofmelasmaasplitfacecomparativestudy
AT foudaibrahim intradermalinjectionoftranexamicacidversusplateletrichplasmainthetreatmentofmelasmaasplitfacecomparativestudy